[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353378-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353378-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","defective-microhomology-mediated-end-joining-in-smarcb1-deficient-tumors","Defective microhomology-mediated end joining in SMARCB1-deficient tumors","","Rhabdoid tumors (RTs) are lethal pediatric cancers driven by biallelic SMARCB1 loss, which disrupts BAF chromatin remodeling integrity. SMARCB1-deficient cells show a defect in the microhomology-mediated end joining (MMEJ) pathway and a reduced protein level of DNA Polymerase theta (PolΘ). Mechanistically, SMARCB1 supports POLQ mRNA nuclear export via nuclear pore complex interactions. Loss of MMEJ triggers compensatory Fanconi Anemia/BRCA pathway activation, creating hyper-dependence. Antitumor efficacy in RT models arises from RBM39 degraders that disrupt FA/BRCA signaling, suggesting broader therapeutic targeting of FA/BRCA in BAF-deficient cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/defective-microhomology-mediated-end-joining-in-smarcb1-deficient-tumors/353378/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/defective-microhomology-mediated-end-joining-in-smarcb1-deficient-tumors/353378.png","ImageObject",300,407,{"name":42,"@type":43},"dhado","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the connection between SMARCB1 loss and the MMEJ DNA repair pathway?","Question",{"text":63,"@type":64},"SMARCB1-deficient tumors show reduced MMEJ activity and decreased Polθ protein, indicating that SMARCB1 is required to maintain the core MMEJ machinery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does SMARCB1 regulate Polθ in cells?",{"text":68,"@type":64},"SMARCB1 promotes POLQ expression mainly by interacting with nuclear pore complex proteins that facilitate nuclear export of POLQ mRNA.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might FA/BRCA pathway inhibition work in SMARCB1-deficient tumors?",{"text":72,"@type":64},"Loss of MMEJ leads to compensatory FA/BRCA activation and hyper-dependence on this pathway, making cells vulnerable to FA/BRCA inhibitors or disruption.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353378,1790524866,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","CANCER  \nDefective microhomology-mediated end joining in SMARCB1-deficient tumors  \nGuangli Zhu1,2†, Shuhei Asada1†*, Huy Nguyen1, Yuna Hirohashi1, Lifang Sun1,  \nAvneesh Saravanapavan3, Erfan Rahmani4, Maryia Hrynashka5, Sirisha Mukkavalli1, Mona Batish5, Geoffrey I. Shapiro6,7, Alan D. D’Andrea1,6,7*  \nRhabdoid tumors (RTs) are highly aggressive cancers driven by biallelic mutation of SMARCB1, a core subunit of the BAF (SWI/SNF) complex. We found that SMARCB1-deficient tumors have a defect in the microhomologymediated end joining (MMEJ) pathway, and SMARCB1 is essential for maintaining the protein level of the core MMEJ protein, DNA Polymerase theta (PolΘ). Mechanistically, SMARCB1 facilitates the nuclear export of the POLQ mRNA through its interaction with the nuclear pore complex. Interestingly, loss of MMEJ in RT cells leads to a compensatory activation of, and a hyper-dependence on, the Fanconi Anemia (FA)/BRCA pathway. Notably, degraders of RBM39, a splicing modulator, show strong antitumor efficacy in RT models in vitro and in vivo by disrupting FA/ BRCA pathway. SMARCB1 and other cBAF/pBAF components are important for maintenance of MMEJ activity and PolΘ protein level, suggesting that BAF-deficient cancers more broadly may be treated by targeted inhibition of the FA/BRCA pathway.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nRhabdoid tumors (RTs) are highly aggressive and lethal pediatric cancers primarily driven by the biallelic inactivation ofSMARCB1, an essential core subunit of the BAF (SWI/SNF) chromatin remodeling complex—specifically its canonical BAF (cBAF) and polybromoassociated BAF (pBAF) assemblies (1, 2) . Loss ofSMARCB1 disrupts BAF complex integrity and function (3, 4), establishing it as the defining genetic alteration in RT. Despite intensive multimodal treatments including surgery, chemotherapy, and radiotherapy, the prognosis remains exceptionally poor, with 5-year survival rates often below 40%(5) . While targeted therapies, such as EZH2 inhibitors, represent a promising treatment strategy for RTs (6, 7), the therapeutic landscape for these tumors remains very limited, and additional molecularly targeted strategies are urgently needed.  \nUnlike other high-grade cancers, RTs are characterized by an extremely low mutation burden and minimal genomic instability, with biallelic SMARCB1 loss representing the only recurrent genetic alteration (8–11). This genomic simplicity is paradoxical, given the aggressive nature of the disease and its sensitivity to specific agents targeting DNA damage repair proteins, such as ATR inhibition (12), suggesting a distinct defect in an error-prone DNA repair pathway. We recently reported that, under replication stress, the loss of the microhomologymediated end joining (MMEJ) pathway sensitizes cells to ATR inhibitors ( 13). Therefore, RTs may have a defect in MMEJ, which would offer opportunities for synthetic lethality strategies.  \n1division of Radiation and Genome Stability, department of Radiation Oncology, dana-Farber cancer institute, harvard Medical School, Boston, MA, USA. 2department of Radiation Oncology, the First Affiliated hospital of Sun Yat-sen University, Guangzhou, china. 3duke University School of Medicine, durham, nc, USA. 4department of Biomedical engineering, University of delaware, newark, de, USA. 5department of Medical and Molecular Sciences, University of delaware, newark, de, USA. 6center for dnA damage and Repair, dana-Farber cancer institute, harvard Medical School, Boston, MA, USA. 7department of Medical Oncology, dana-Farber cancer institute, harvard Medical School, Boston, MA, USA.  \n*[corresponding author. email:](corresponding author. email:) [shuhei_asada@dfci.harvard.edu](shuhei_asada@dfci.harvard.edu) (S.A.","cbCaib5EEhwybwjC","https://ap.wps.com/l/cbCaib5EEhwybwjC","pdf",2378260,15,"English","# Introduction\n## Rhabdoid tumors and SMARCB1-driven chromatin defects\n## DNA repair pathway context and rationale for targeting MMEJ/FA-BRCA\n## DNA repair roles of MMEJ, Polθ, and FA/BRCA\n## Current report design and mechanistic findings","[{\"question\":\"What is the connection between SMARCB1 loss and the MMEJ DNA repair pathway?\",\"answer\":\"SMARCB1-deficient tumors show reduced MMEJ activity and decreased Polθ protein, indicating that SMARCB1 is required to maintain the core MMEJ machinery.\"},{\"question\":\"How does SMARCB1 regulate Polθ in cells?\",\"answer\":\"SMARCB1 promotes POLQ expression mainly by interacting with nuclear pore complex proteins that facilitate nuclear export of POLQ mRNA.\"},{\"question\":\"Why might FA/BRCA pathway inhibition work in SMARCB1-deficient tumors?\",\"answer\":\"Loss of MMEJ leads to compensatory FA/BRCA activation and hyper-dependence on this pathway, making cells vulnerable to FA/BRCA inhibitors or disruption.\"}]","Defective microhomology-mediated end joining in SMARCB1-deficient tumors | PDF",1790105003,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb764f7c8d21d6f29a847f29f38283a9.webp",983,1250,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8ef3ed2f5135b8aa9ac1af3838bf28a.webp",982,1249,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61395b160068cd7048fe6e6d0e2b7a18.webp",981,1248,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/825c6da59b8c60c7ffb60f0a1d42f0b0.webp",980,1247]